MLICM
NVCT icon

Metropolitan Life Insurance Company (MetLife)’s Nuvectis Pharma NVCT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-411
Closed -$6.56K – 2432
2023
Q2 		$6.56K Buy
+411
New +$6.56K ﹤0.01% 2442

Other funds holding NVCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s NVCT Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Nuvectis Pharma (NVCT) in Q3 2023, closing a stake of 411 shares — an estimated $6.56K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in NVCT in Q2 2023 and held it in 1 quarter. The position peaked at $6.56K in Q2 2023. 33 funds tracked by Wall St. Rank hold NVCT as of Q3 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Nuvectis Pharma position as of Q3 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 411 Nuvectis Pharma shares in Q3 2023, an estimated $6.56K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Nuvectis Pharma in Q2 2023 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Nuvectis Pharma position peaked at $6.56K in Q2 2023.
  • 33 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.